This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MedChi Applauds Maryland Senate For Expanding Patient Access To Innovative Drugs

ANNAPOLIS, Md., March 11, 2013 /PRNewswire/ -- MedChi, The Maryland State Medical Society, applauds passage of legislation in the Maryland State Senate to create a process that will make newly developed biosimilar medications accessible in a safe and transparent manner for state residents. The legislation still has to pass hurdles in the House and be signed by the Governor to become law.

"Biosimilar drugs are now being used in Europe and will soon be authorized for patient use in this country," explained MedChi CEO Gene Ransom. " Maryland is being proactive in establishing a process by which patients have access to these affordable drugs with provisions to protect their safety."

The committee action fulfills the state's responsibilities under the federal Affordable Care Act (ACA). The ACA empowers states to set the standards by which biosimilars -- reproductions of brand-name biologic medications -- can be substituted for the innovator product. It is expected that biosimilars will be reaching pharmacies as early as 2014.

The State Senate measure, introduced by Sen. Joan Carter Conway, states that biosimilars can only be substituted if the Food and Drug Administration has certified the drugs as interchangeable with the original, brand-name biologic. This standard is made necessary by the fact that, unlike generic versions of conventional drugs, biologics are made from living cells and it is impossible to create exact copies. Even slight variations between the biologic and the biosimilar can make a difference in clinical outcomes.

Ransom explained, "Biologics are changing the lives of patients with serious chronic illnesses. Biosimilars will make this improved health financially accessible for more Marylanders, but because of the unique nature of these medications, patient safety must be assured. This committee action provides both accessibility and critical safeguards. This is common-sense, patient-centric legislation."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs